News

Sigyn Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

SmallCaps Daily March 8, 2021

317 3 minutes read

[ad_1]

San Diego – (NewMediaWire) – March 8, 2021 – Sigyn
Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on
the treatment of life-threatening inflammatory conditions precipitated by
Cytokine Storm Syndrome (the Cytokine Storm), today announced that Jim Joyce,
its Chairman and Chief Executive Officer, will present at the H.C. Wainwright
Global Life Sciences Conference that will take place virtually tomorrow March
9th and Wednesday March 10, 2021.

To register for the event,
please visit: https://my.ct.events/register.aspx?meid=fc99b171-2574-4558-bda3-3ba391b6e555&rpid=75ab29bf-f328-45e8-9008-d5e88edeea28

Mr. Joyce’s presentation will be
available beginning March 9, 2021 at 7:00am EST and can also be accessed at the
investor relations section of the Sigyn Therapeutics website at www.sigyntherapeutics.com

About Sigyn Therapeutics

Sigyn Therapeutics™ is a
development-stage therapeutic technology company headquartered in San Diego,
California USA. Our focus is directed toward a significant unmet need in global
health; the treatment of life-threatening inflammatory conditions that are
precipitated by Cytokine Storm Syndrome and not addressed with an approved
therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood
purification technology designed to mitigate cytokine storm syndrome through
the broad-spectrum depletion of inflammatory targets from the bloodstream.
Cytokine storm syndrome is the hallmark of sepsis, which is the most common
cause of in-hospital deaths and claims more lives each year than all forms of
cancer combined. Virus induced cytokine storm (VICS) is associated with high
mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other
therapeutic opportunities include, but are not limited to bacteria induced
cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute
forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com

Cautionary Note Regarding
Forward-Looking Statements

This press release contains
forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve
substantial risks and uncertainties. All statements contained in this press
release are forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,”
“intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative
of these terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements include, among
others, statements about Sigyn’s future financial performance, the impact of
management changes, any proposed organizational restructuring, results of
operations, capital resources to fund operations; statements about Sigyn’s
expectations regarding the capitalization, resources and ownership structure of
the combined company; statements about the potential benefits of the
transaction; the expected completion and timing of the transaction and other
information relating to the transaction; and any other statements other than
statements of historical fact. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in the forward-looking
statements that Sigyn makes due to a number of important factors, including (i)
the risk that the transaction may not be completed in a timely manner or at
all, which may adversely affect Sigyn’s business and the price of the common
stock of Sigyn, (ii) the failure to satisfy of the conditions to the
consummation of the transaction, (iii) the occurrence of any event, change or other
circumstance that could give rise to the termination of the merger agreement,
(iv) risks related to the ability to realize the anticipated benefits of the
transaction, including the risk that the businesses will not be integrated
successfully, (v) the effect of the announcement or pendency of the transaction
on Sigyn’s business relationships, operating results and business generally,
(vi) risks that the proposed transaction disrupts current plans and operations,
(vii) risks related to the combined entity’s ability to up-list to a national
securities exchange, (viii) risks related to the combined entity’s access to
existing capital and fundraising prospects to fund its ongoing operations, (ix)
risks related to diverting management’s attention from Sigyn’s ongoing business
operations, (x) other business effects, including the effects of industry,
market, economic, political or regulatory conditions, future exchange and
interest rates, and changes in tax and other laws, regulations, rates and
policies, and (xi) risks related to an inability to manufacture Sigyn Therapy,
risks related to the clinical advancement of Sigyn Therapy with regulatory
agencies, and no assurance that Sigyn Therapy will be proven to be a safe and
efficacious treatment for any condition. The forward-looking statements in this
press release represent Sigyn’s views as of the date of this press release.
Sigyn anticipates that subsequent events and developments may cause its views
to change. However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims any
obligation to do so. You should, therefore, not rely on these forward-looking
statements as representing Sigyn’s views as of any date subsequent to the date
of this press release.